Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of CER-001 for treatment of sever eye disorder

Next Previous
Trial Profile

A clinical trial of CER-001 for treatment of sever eye disorder

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CER 001 (Primary)
  • Indications Eye disorders
  • Focus Therapeutic Use

Most Recent Events

  • 24 Mar 2024 New trial record
  • 14 Mar 2024 According to an ABIONYX Pharma media release, the company has received eur1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology. This grant will help finance studies on the CER-001 drug candidate. Payment will be made in two instalments, once development has begun and company has made the corresponding investment in its 100per cent ophthalmology subsidiary, Apogeye Pharma.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top